Global Pericarditis Drugs Market 2019-2023

The global pericarditis drugs market size will grow by USD 422.53 million during 2019-2023. This report provides a detailed analysis of the market by product (NSAIDs, colchicine, and others) and geography (Asia, Europe, North America, and ROW). The report analyzes the market’s competitive landscape and offers information on several pericarditis drug manufacturers including AstraZeneca Plc, Bayer AG, Johnson & Johnson Services Inc., Pfizer Inc., and Takeda Pharmaceutical Co. Ltd.

Some of the key findings from this pericarditis drugs market forecast report are summarized below

See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from this report.

Get a FREE sample now!

Global pericarditis drugs industry overview

Clinical trials on the combination of aspirin and colchicine have shown significant results in reducing the recurrence rate of idiopathic pericarditis in patients compared to conventional monotherapy. Dual therapy also had a significant impact on lowering the symptoms of pericarditis at a 72-hour interval without any side effects. Such advantages have increased the adoption of dual therapy for the treatment of recurrent pericarditis. Moreover, the rising prevalence of idiopathic pericarditis is also anticipated to increase the demand for dual therapy. This will subsequently drive the growth of the global pericarditis drugs market size during the forecast period.

Additionally, the advent of biologics is also one of the major factors that will fuel the growth of the pericarditis drugs market size. Anakinra was traditionally used for the treatment of rheumatoid arthritis. The drug is also approved by the US FDA for the treatment of various other diseases including colchicine-resistant familial Mediterranean fever (FMA) and tumor necrosis factor receptor-associated periodic syndrome (TRAPS). Moreover, pericarditis is considered as the most common indication of FMF and TRAPS and the use of anakinra is effective in reducing recurrent pericarditis episodes. More detailed studies on the use of anakinra coupled with the adoption of dual therapy, will drive global pericarditis drugs market at a CAGR of over 4% during 2019-2023.

Top pericarditis drugs companies covered in this market research report

The global pericarditis drugs market is fairly fragmented. This research report provides a detailed analysis of the market’s competitive landscape and provides information on the products offered by various companies. Key insights provided by this pericarditis drugs market report will help companies create effective strategies to improve their revenue share.

The report offers a detailed analysis of several leading companies including:

• AstraZeneca Plc
• Bayer AG
• Johnson & Johnson Services Inc.
• Pfizer Inc.
• Takeda Pharmaceutical Co. Ltd.

Pericarditis drugs market segmentation based on product

• NSAIDs
• Colchicine
• Others

NSAIDs will account for the largest pericarditis market share. The high therapeutic efficacy, abundant availability, and the affordability of NSAID drugs are driving the growth of this market segment. Moreover, the use of NSAID drugs such as naproxen as an alternative for the treatment of pericarditis and related comorbidities will also contribute to the growth of the market in this segment.

Pericarditis drugs market segmentation based on geography

• Asia
• Europe
• North America
• ROW

North America will provide the largest growth opportunities for pericarditis drug companies. The strong prevalence of pericarditis in patients with cardiovascular diseases has increased the demand for pericarditis drugs in the region. The increased expenditure on healthcare in the US and the rising investments in the R&D by large pharmaceutical vendors will also contribute to the growth of the pericarditis drugs market size in North America.

Key highlights of the global pericarditis drugs market report for the forecast period 2019-2023

• CAGR of the market during the forecast period 2019-2023
• Detailed information on factors that will accelerate the growth of the pericarditis drugs market size during the next five years
• Precise estimation of the global pericarditis drugs market size and its contribution to the parent market
• Accurate predictions on upcoming trends and changes in consumer behavior
• The growth of the pericarditis drugs industry across Asia, Europe, North America, and ROW
• A thorough analysis of the market’s competitive landscape and detailed information on several vendors
• Comprehensive details of factors that will challenge the growth of pericarditis drug companies 

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch